- Home
- ONCO vs QNRX Comparison
ONCO vs QNRX Comparison
Compare ONCO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- QNRX
- Stock Information
- Founded
- ONCO 2018
- QNRX 2018
- Country
- ONCO United States
- QNRX United States
- Employees
- ONCO N/A
- QNRX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- ONCO Health Care
- QNRX Health Care
- Exchange
- ONCO Nasdaq
- QNRX Nasdaq
- Market Cap
- ONCO 3.3M
- QNRX 3.0M
- IPO Year
- ONCO 2022
- QNRX N/A
- Fundamental
- Price
- ONCO $0.43
- QNRX $0.56
- Analyst Decision
- ONCO
- QNRX Strong Buy
- Analyst Count
- ONCO 0
- QNRX 1
- Target Price
- ONCO N/A
- QNRX $4.00
- AVG Volume (30 Days)
- ONCO 282.9K
- QNRX 2.4M
- Earning Date
- ONCO 12-24-2024
- QNRX 11-07-2024
- Dividend Yield
- ONCO N/A
- QNRX N/A
- EPS Growth
- ONCO N/A
- QNRX N/A
- EPS
- ONCO N/A
- QNRX N/A
- Revenue
- ONCO $1,870,605.00
- QNRX N/A
- Revenue This Year
- ONCO N/A
- QNRX N/A
- Revenue Next Year
- ONCO N/A
- QNRX N/A
- P/E Ratio
- ONCO N/A
- QNRX N/A
- Revenue Growth
- ONCO N/A
- QNRX N/A
- 52 Week Low
- ONCO $0.37
- QNRX $0.48
- 52 Week High
- ONCO $21.40
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- ONCO 22.61
- QNRX 37.41
- Support Level
- ONCO $0.37
- QNRX $0.72
- Resistance Level
- ONCO $0.47
- QNRX $0.87
- Average True Range (ATR)
- ONCO 0.10
- QNRX 0.14
- MACD
- ONCO 0.10
- QNRX -0.02
- Stochastic Oscillator
- ONCO 15.28
- QNRX 2.13
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.